Celcuity (CELC) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Loss: $43.8 million ($0.92 per share) for Q3 2025, compared to a net loss of $29.8 million ($0.70 per share) in Q3 2024.

Non-GAAP Adjusted Net Loss: $37.2 million ($0.78 per share) for Q3 2025, up from $27.6 million ($0.65 per share) in Q3 2024.

Research and Development Expenses: Increased to $34.9 million from $27.6 million year-over-year, primarily due to increased personnel and consulting costs related to commercial preparations.

General and Administrative Expenses: Rose to $7.9 million from $2.5 million, largely due to higher employee and consulting expenses.

Cash Position: Ended the quarter with approximately $455 million in cash, cash equivalents, and short-term investments, bolstered by $287 million from concurrent offerings and an amended term loan facility totaling $500 million.

2Strategic Updates and Business Highlights

Clinical Milestones: Released positive top-line data from the PIK3CA wild-type cohort of the Phase III VICTORIA-one study, showing significant improvements in median progression-free survival (PFS) compared to fulvestrant.

FDA Submission: The FDA accepted a request for a new drug application (NDA) under the real-time oncology review program for getetelicib, with submission expected by the end of Q4 2025.

Commercial Launch Preparations: Accelerated efforts for the potential launch of getetelicib, including hiring a sales force and engaging with key opinion leaders and payers.

Market Opportunity: Estimated total addressable market for getetelicib in the second-line setting is $5 billion to $6 billion, with potential peak revenues of $2.5 billion to $3 billion.

3Forward Guidance and Outlook

Cash Runway: Current cash and investments expected to fund operations through 2027.

Regulatory Submissions: Anticipated submission for the wild-type population by the end of Q4 2025, with potential for a real-time oncology review for mutant data depending on results.

Market Penetration: Management is optimistic about achieving significant market share in the second-line setting for HR-positive, HER2-negative breast cancer.

4Bad News, Challenges, or Points of Concern

Increased Losses: The significant increase in net loss and operating cash burn raises concerns about financial sustainability without successful product launches.

Regulatory Risks: The success of the NDA submission and future approvals for mutant populations remain uncertain and could impact growth projections.

Market Competition: The competitive landscape in oncology, particularly for breast cancer therapies, poses challenges for establishing getetelicib as a new standard of care.

5Notable Q&A Insights

Data Presentation: Additional data is expected to be presented at the San Antonio Breast Cancer Symposium, including subgroup analyses.

Enrollment Impact: Positive results from the VICTORIA-one study are anticipated to enhance enrollment in the ongoing VICTORIA-two study.

Pricing Strategy: Pricing for getetelicib is still under consideration, with benchmarks around $25,000 based on recent drug launches in the same therapeutic area.

International Expansion: Plans to commercialize outside the U.S. are contingent on the success of regulatory submissions, with discussions expected to begin mid-2026. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and concerns highlighted during the earnings call, providing a comprehensive overview of Celcuity's current position and outlook.